Ocuphire Pharma, Inc. (OCUP)

1,7000 +0,0200 (+1,19%) Börsenschluss: 04:00PM EDT

Ocuphire Pharma, Inc.

37000 Grand River Avenue
Suite 120
Farmington Hills, MI 48335
United States
(248) 957-9024
https://www.ocuphire.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 14

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. George Magrath M.B.A., M.D., M.S.	CEO & Director	625,07k	N/A	1984
Mr. Bernhard Hoffmann M.B.A.	Senior Vice President of Corporate Development & Secretary	434,1k	N/A	1956
Ms. Amy Zaremba Rabourn C.P.A., MAcc	Senior Vice President of Finance	434,1k	N/A	1981
Mr. Nirav Suresh Jhaveri C.F.A.	Chief Financial Officer	N/A	N/A	1978
Mr. Joseph K. Schachle MBA	Chief Operating Officer	N/A	N/A	1965
Dr. Ashwath Jayagopal Ph.D.	Chief Scientific & Development Officer	N/A	N/A	1982
Ms. Bindu Manne	Head of Market Development & Commercialization	N/A	N/A	N/A
Mr. Erik Sims	Director & Corporate Controller	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Corporate Governance

Ocuphire Pharma, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.